InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,868.40
(
-0.79%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.10
(
-0.14%
)
Bitcoin
64,690.88
(
0.62%
)
Post# of 29247
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119468
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 17046

Sunday, 09/23/2018 6:07:34 PM

Sunday, September 23, 2018 6:07:34 PM

Post# of 29247
ABT’s MitraClip meets all endpoints in secondary mitral regurgitation:

https://finance.yahoo.com/news/landmark-study-shows-treatment-abbotts-172000535.html

Secondary mitral regurgitation is a considerably larger market than MitraClip’s approved indication in primary mitral regurgitation, so this trial could move the needle even for a company as large as ABT.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up